Equity

Additional Paid-In Capital

Thermo Fisher Scientific Additional Paid-In Capital increased by 0.8% to $18.71B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.3%, from $18.11B to $18.71B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows an upward trend with a 3.6% CAGR.

Analysis

StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 1, 2026

How to read this metric

An increase indicates equity financing or the issuance of shares for employee compensation, signaling capital raising or dilution.

Detailed definition

This represents the excess amount paid by shareholders for common stock over its par value. It is a primary component of...

Peer comparison

Standard equity account for all publicly traded companies.

Metric ID: equity_additional_paid_in_capital_common_stock

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$15.83B$15.96B$16.17B$16.29B$16.47B$16.60B$16.74B$16.89B$17.03B$17.17B$17.29B$17.48B$17.65B$17.83B$17.96B$18.11B$18.23B$18.33B$18.56B$18.71B
QoQ Change+0.8%+1.3%+0.7%+1.1%+0.8%+0.9%+0.9%+0.8%+0.8%+0.7%+1.1%+1.0%+1.0%+0.7%+0.8%+0.7%+0.5%+1.3%+0.8%
YoY Change+4.1%+4.0%+3.5%+3.7%+3.4%+3.4%+3.2%+3.5%+3.6%+3.9%+3.9%+3.6%+3.3%+2.8%+3.3%+3.3%
Range$15.83B$18.71B
CAGR+3.6%
Avg YoY Growth+3.5%
Median YoY Growth+3.5%
Current Streak19+ quarters growth

Frequently Asked Questions

What is Thermo Fisher Scientific's additional paid-in capital?
Thermo Fisher Scientific (TMO) reported additional paid-in capital of $18.71B in Q1 2026.
How has Thermo Fisher Scientific's additional paid-in capital changed year-over-year?
Thermo Fisher Scientific's additional paid-in capital increased by 3.3% year-over-year, from $18.11B to $18.71B.
What is the long-term trend for Thermo Fisher Scientific's additional paid-in capital?
Over 5 years (2020 to 2025), Thermo Fisher Scientific's additional paid-in capital has grown at a 3.6% compound annual growth rate (CAGR), from $15.58B to $18.56B.
What does additional paid-in capital mean?
The total amount of money investors paid for shares above the nominal par value.